According to the researchers, in the phase 1/2a trial, those assigned a single dose of the ligand-conjugated antisense oligonucleotide had reduced Lp(a) concentration at 30 days compared with ...

Added to this is Ionis' Ligand Conjugated Antisense ("LICA") technology ... Both QALSODY and SPINRAZA are administered via lumbar puncture, allowing them to target the central nervous system ...

Now, researchers at Cold Spring Harbor Laboratory report they have developed a potential therapeutic for DIPG using antisense oligonucleotide ... His efforts led to Spinraza ®, the first FDA ...

Ionis Pharmaceuticals is paying $45 million upfront for the exclusive right to binders for the delivery of oligonucleotides ... Bicycle to develop ligand conjugated antisense medicines that ...

Sanofi has entered into a collaboration and license agreement with Alloy Therapeutics to develop an antisense oligonucleotide ... field include Biogen’s ASO Spinraza (nusinersen) approved ...

Spinraza is delivered via intrathecal injection, also known as lumbar puncture. The route of delivery gets the antisense oligonucleotide into the cerebrospinal fluid and thereby provides direct ...

The venture capital firm Atlas Venture is launching a start-up that aims to develop antisense ... Oligonucleotide Therapeutics Society annual meeting this week. The start-up says the ligand ...

today announced that they have entered into a collaboration to discover and develop peptide-conjugated targeted antisense oligonucleotide (ASO) therapeutics. The collaboration will leverage Orbit’s ...